Introduction
Endoscopic mucosal resection (EMR) is an accepted treatment for those early gastric cancers (EGC) associated with a minimal risk of regional lymph node (LN) metastasis [1, 2] . EMR is currently considered appropriate for well differentiated lesions less than 2 cm in diameter without central ulceration. It is recognised that lymphatic-vascular involvement, ulcer formation, and tumor size above 3 cm are independent risk factors for LN metastasis in EGCs limited to the mucosa [3] . Several institutions have suggested that the indications for gastric EMR should be widened [4] [5] [6] . However, any revision of the indications must be based on the evaluation of a large number of cases to provide sufficient statistical power. We reviewed a large series of gastrectomies to propose a revised list of indications for local treatment, including EMR, of EGC.
Patients and methods
A total of 5265 patients who had undergone gastrectomy with LN dissection for EGC at the National Cancer Center Hospital and the Cancer Institute Hospital were studied; 3016 lesions (57.2%) were intramucosal cancers and 2249 (42.8%) penetrated the submucosa. Only 65 (2.2%) intramucosal cancers were associated with regional lymph node metastases. In comparison, 402 cancers invading the submucosa (17.9%) were associated with nodal metastases. The clinical and pathological features of the lesions were assessed by univariate analysis to determine which factors predicted the presence of nodal metastases.
The following features were looked at: sex; age; and tumor (location, macroscopic appearance, size, presence or absence of ulceration of the lesion, the two major histological types [differentiated or undifferentiated lesions], lymphatic-vascular involvement, and deAbstract Background. The presence of lymph node metastasis (LNM) is the most important prognostic factor for patients with early gastric cancer (EGC). A D2 gastrectomy has been the gold standard treatment. Strict criteria for endoscopic mucosal resection have been widely accepted in Japan. There are some trials aimed at expanding the indications for local treatment, although there has not been a comprehensive review of the risk of LNM with the lesions of EGC. Methods. We investigated 5265 patients who had undergone gastrectomy with lymph node dissection for EGC at the National Cancer Center Hospital and the Cancer Institute Hospital. Nine clinicopathological factors were assessed for their possible association with LNM. Results. None of the 1230 well differentiated intramucosal cancers of less than 30 mm diameter regardless of ulceration findings, were associated with metastases (95% confidence interval [CI], 0-0.3%). None of the 929 lesions without ulceration were associated with nodal metastases (95% CI, 0-0.4%) regardless of tumor size. Similarly to findings for intramucosal cancers, for submucosal lesions, there was a significant correlation between tumor size larger than 30 mm and lymphatic-vascular involvement with an increased risk of LNM. None of the 145 differentiated adenocarcinomas of less than 30-mm-diameter without lymphatic or venous permeation were associated with LNM, provided that the lesion had invaded less than 500 µm into the submucosa (95% CI, 0-2.5%). Conclusion. Based on our large series of cases, we have been able to clarify the risks associated with EGC and to propose expansion of the criteria for local treatment. However, accurate histological evaluation of the resected specimens is essential to avoid recurrence for such EGCs that should be cured.
gree of submucosal penetration). The Japanese classification of gastric carcinoma was used to classify the endoscopic appearance of the lesions [7] . Well and moderately differentiated tubular adenocarcinomas and papillary adenocarcinomas were grouped together as "differentiated lesions". Poorly differentiated adenocarcinomas and signet-ring cell carcinomas were classified as "undifferentiated histological types" [7] . Lesions with ulceration or scarring from previous ulceration (converging folds or deformity of the muscularis propria, or fibrosis in the submucosal or deeper layer) within them were regarded as "ulcerated lesions". The depth of submucosal invasion was measured from the muscularis mucosa to the point of deepest penetration. The depth of submucosal penetration was classified into two subgroups: SM1 (р500 µm penetration into submucosa) and SM2 (Ͼ500 µm). All histological sections were examined by three pathologists (Y.K., A.Y., and T.S.).
Statistical analysis was carried out using the SAS program (SAS Institute, Cary, NC, USA). The association of LN metastasis with clinicopathological variables was assessed using the simple test, with P Ͻ 0.01 considered significant. The probability of LN metastasis was estimated with 95% confidence intervals (95% CI), based on the exact binominal distribution.
Results

Intramucosal cancer
The relationship between different clinical and pathological factors and the risk of LN metastases is summarized in Table 1 . Depressed or ulcerated lesions, larger than 30 mm, of the undifferentiated histological type, with invasion into lymphatics or venules, were associated with an increased risk of nodal metastases. In contrast, none of the 1230 differentiated less than 30 mm in size, regardless of ulceration, were associated with metastases (95% CI, 0-0.3%) ( Table 2 ). None of the 929 lesions without ulceration were associated with nodal metastases (95% CI, 0-0.4%) regardless of the size of the lesion.
The overall risk of LN metastases in histologically undifferentiated lesions was 4.2%. However, none of the 141 undifferentiated lesions without ulceration, less than 20 mm in size, were associated with positive lymph nodes (95% CI, 0-2.6%). 
Submucosal invasive cancer
Similarly to the findings for intramucosal cancers, there was a significant correlation between tumor size larger than 30 mm and lymphatic-vascular involvement with an increased risk of LN metastases. In addition, those cancers penetrating deeply into the submucosa were the most likely to be associated with regional LN metastases (Table 3) . The relationship between LN metastasis and tumor characteristics such as size, depth of submucosal invasion, presence of ulceration, differentiation, and lymphatic or vascular permeation is shown in Table 4 . For well differentiated tumors, subgroup analysis based on the pairing of individual factors such as tumor size, depth of submucosal penetration, and lymphatic-vascular involvement failed to yield a subgroup entirely free of nodal metastasis. However, the subgroup of 145 lesions with a size less than 30 mm, well differentiated histology, lack of lymphatic-vascular invasion, and submucosal penetration of less than 500 µm was entirely free of nodal metastasis (95% CI, 0-2.5%).
Discussion
EGC is defined as that in which tumor invasion is confined to the mucosa or submucosa, irrespective of the presence of regional LN metastasis [7] . Because it is recognized that the presence of LN metastasis has a strong adverse influence on the prognosis of patients with EGC [8] [9] [10] , radical surgery with the complete removal of the first and second tier LNs has become the gold standard treatment for patients with EGCs [11] [12] , with 5-year survival rates being in excess of 90%, including recent European series [10] [11] [12] [13] [14] [15] [16] . In our own series from the National Cancer Center in Japan, the 5-year survival rates in patients with intramucosal and submucosal invasive cancers, excluding noncancerous deaths, were 99% and 96%, respectively [14] . However, the incidence of LN metastasis in intramucosal and submucosal EGCs has been reported as approximately 3% and 20%, respectively [17] [18] [19] [20] [21] [22] [23] ; therefore, surgery may be excessive in many patients with these lesions. Considering the risks of gastrectomy and the negative effect on the patient's quality of life [24] [25] [26] [27] [28] [29] , if a group of patients with a negligible risk of LN metastasis can be defined, it is sensible to offer a local treatment for them. EMR for selected intramucosal EGC, for which the possibility of LN metastasis is almost zero, has been widely accepted as a therapeutic strategy for cure in Japan. Currently, the accepted indications for EMR are: (1) well differentiated elevated lesions less than 20 mm in size, and (2) small (Յ10 mm) depressed well differentiated tumors without ulceration [30] . However, these criteria are rather strict, and currently, many patients may be subjected to unnecessary surgery. Therefore many Japanese investigators have suggested possible extended criteria for local treatment (Table 5 [ 3, 5, [31] [32] [33] [34] [35] ). The upper limit of the 95% CI calculated from these reports, because of the small sample size, was too large to exclude the possibility of LN metastasis. Previous reviews have been based on smaller series, providing large confidence intervals when the risk of lymph node metastasis is being calculated. Based on our larger series of cases, we have been able to clarify the risks associated with different lesions further, and we propose an expansion of the criteria for local treatment (Table 6 ). These criteria are based on complete histological examination of the resected specimen. The findings for some factors, especially lack of lymphatic-vascular involvement, or SM1 grade, which are associated with a minimal risk of LN metastasis, are available only after histological examination of the entire resected specimen. Therefore, it is of paramount importance that the specimen is resected in such a way that an accurate histological examination can be carried out.
When expansion of local treatment for patients with EGC is considered, it is essential to accurately evaluate the resected specimen to determine whether an additional surgical procedure is warranted. The method of local treatment varies among institutions, depending on the techniques used to make such evaluations.
There are several techniques for endoscopic mucosal resection. Korenaga et al. [17] reported that depth of penetration was difficult to assess correctly in lesions larger than 15 mm resected piecemeal. At the National Cancer Center, a new technique, using an insulatedtipped (IT) needle knife has been invented to allow the endoscopic en-bloc resection of larger lesions [36] . If resected en-bloc, even lesions larger than 15 mm can be examined as accurately as surgically resected material. With the IT knife, we are now offering EMR for many patients who would have been treated by surgical intervention.
It is difficult to determine clinically whether lesions are confined to the mucosa or whether they are likely to penetrate the submucosa. Reported series have indicated that the endoscopic assessment of depth of pen- SM1, Penetration of submucosal layer less than 500 µm from muscularis mucosa; SM2, penetration of 500 µm or more etration is inaccurate in up to 20% of lesions [37, 38] . Biopsies are too superficial to provide this information, but EMR provides a larger specimen, which allows assessment of depth of invasion and lymphatic-vascular involvement. Considering that the pretreatment diagnosis could be incorrect for 20% of the tumors that are candidates for local treatment, it is essential to make an accurate histological evaluation of the resected specimens to avoid recurrence of such early lesions that should be cured. [31] Intramucosal elevated lesion, tumor less than 2.5 cm in size 0/21; 0% 0-16.1% Intramucosal depressed lesion, without ulcer findings, tumor less than 0/113; 0% 0-3.2% 2 cm in size Ohgami [32] Intramucosal protruded lesion, tumor less than 2.5 cm in size 0/67; 0% 0-5.4% Yasuda [5] Submucosal invasive cancer less than 300 µm in depth, tumor less 0/12; 0% 0-26.5% than 1 cm in size Oizumi [33] Submucosal invasive cancer, tumor less than 1 cm in size 0/28; 0% 0-12.3% Fujii [34] Submucosai invasive cancer, tumor less than 1 cm in size 0/14; 0% 0-23.2% Gotoda [35] Differentiated adenocarcinoma, no lymphatic-vascular invasion, tumor 0/117; 0% 0-3.1% less than 3 cm in size, submucosal invasive cancer less than 500 µm in depth EMR, Endoscopic mucosal resection Table 6 . Criteria for expansion of local treatment, derived from our results
Criteria
Incidence 95% CI Intramucosal cancer 0/1230; 0% 0-0.3% differentiated adenocarcinoma, no lymphatic-vascular invasion, irrespective of ulcer findings, tumor less than 3 cm in size Intramucosal cancer 0/929; 0% 0-0.4% differentiated adenocarcinoma, no lymphatic-vascular invasion, without ulcer findings, irrespective of tumor size Undifferentiated intramucosal cancer 0/141; 0% 0-2.6% no lymphatic-vascular invasion, without ulcer findings, tumor less than 3 cm in size Minute submucosal penetration (SM1) 0/145; 0% 0-2.5% differentiated adenocarcinoma, no lymphatic-vascular invasion, tumor less than 3 cm in size
